每日剂量与他汀类药物种类和开角型青光眼风险的关联
基于2001年1月至2009年12月的索赔数据,观察25420例无既存青光眼患者,量化他汀及其他降胆固醇药物暴露;校正基线低密度脂蛋白水平后,连续2年填写他汀处方者青光眼风险较未使用者降低21%(校正HR 0.79,95%CI 0.66-0.96,P=0.02)。最高剂量80 mg与较低剂量40 mg相比无额外保护作用,各他汀种类与阿托伐他汀相比风险无差异。
要点
- 连续2年填写他汀处方者青光眼风险较未使用者降低21%(校正HR 0.79,95%CI 0.66-0.96,P=0.02)。
- 最高剂量80 mg与较低剂量40 mg相比无额外保护作用(HR 1.03,95%CI 0.59-1.80,P=0.91)。
- 各他汀种类与阿托伐他汀相比对开角型青光眼风险无差异。
核心结论
- 即使校正基线低密度脂蛋白水平,他汀暴露仍与开角型青光眼风险降低相关。
- 本研究有助于为设计评估他汀使用与青光眼关联的随机临床试验的研究者提供合理的他汀每日剂量与种类的参考。
研究设计与样本
- 利用2001年1月至2009年12月的索赔数据,观察25420例无既存青光眼患者,量化他汀及其他降胆固醇药物暴露。
- 采用多变量回归模型评估发生开角型青光眼的危险度,并分析其随他汀每日剂量或种类的变化,以及校正基线低密度脂蛋白水平后保护效应是否持续。
主要发现
- 25420例符合纳入标准患者平均(SD)年龄66.1(5.8)岁,14112例(55.5%)为女性;19232例(84.1%)为白人,1252例(5.5%)为黑人,1558例(6.8%)为拉丁裔。
- 校正基线低密度脂蛋白水平后,连续2年填写他汀处方者较未使用者青光眼风险降低21%(校正HR 0.79,95%CI 0.66-0.96,P=0.02)。
- 最高剂量80 mg与较低剂量40 mg相比无额外保护作用(HR 1.03,95%CI 0.59-1.80,P=0.91)。
- 与阿托伐他汀相比,洛伐他汀(HR 1.09,95%CI 0.71-1.68,P=0.69)、西立伐他汀(HR 0.61,95%CI 0.09-4.41,P=0.63)、瑞舒伐他汀(HR 0.83,95%CI 0.48-1.44,P=0.51)、氟伐他汀(HR 0.89,95%CI 0.39-2.02,P=0.78)、普伐他汀(HR 1.29,95%CI 0.93-1.79,P=0.13)和辛伐他汀(HR 1.03,95%CI 0.83-1.29,P=0.78)对开角型青光眼风险的保护效应无差异。
关键数值与推荐
- 连续2年填写他汀处方者较未使用者青光眼风险降低21%(校正HR 0.79,95%CI 0.66-0.96,P=0.02)。
- 最高剂量80 mg与较低剂量40 mg相比无额外保护作用(HR 1.03,95%CI 0.59-1.80,P=0.91)。
- 与阿托伐他汀相比,洛伐他汀HR 1.09(95%CI 0.71-1.68,P=0.69),西立伐他汀HR 0.61(95%CI 0.09-4.41,P=0.63),瑞舒伐他汀HR 0.83(95%CI 0.48-1.44,P=0.51),氟伐他汀HR 0.89(95%CI 0.39-2.02,P=0.78),普伐他汀HR 1.29(95%CI 0.93-1.79,P=0.13),辛伐他汀HR 1.03(95%CI 0.83-1.29,P=0.78)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is growing evidence that statins may protect against the development or worsening of open-angle glaucoma (OAG). As researchers plan clinical trials to more definitively study whether statins indeed protect against OAG, it would be helpful to know whether specific daily dosages or types of statin confer a greater protective effect than others. OBJECTIVE: To assess whether the protective effect of statins on the risk of glaucoma varies depending on the daily dosage or type of statin taken. DESIGN, SETTING, AND PARTICIPANTS: Using claims data from January 2001 to December 2009, we observed 25 420 patients with no preexisting glaucoma and quantified exposure to statins and other cholesterol-lowering medications. Using multivariable regression modeling, we assessed the hazard of developing OAG and how it varied by the daily dosage or type of statin and whether any protective effect persists after accounting for baseline low-density lipoprotein level. EXPOSURES: Different daily dosages and types of statins. MAIN OUTCOMES AND MEASURES: Hazard ratios (HRs) for developing OAG with 95% CIs. RESULTS: Of the 25 420 patients who met the eligibility criteria for study inclusion, the mean (SD) age was 66.1 (5.8) years, and 14 112 (55.5%) were female. Additionally, 19 232 patients (84.1%) were white, 1252 (5.5%) were black, and 1558 (6.8%) were Latino. After accounting for baseline low-density lipoprotein levels, persons who filled prescriptions for statins continuously for 2 years had a 21% reduced risk of glaucoma compared with nonusers (adjusted HR, 0.79; 95% CI, 0.66-0.96; P = .02). There was no additional protective effect associated with taking the highest dosage of statins (80 mg) compared with a lower dosage (40 mg) (HR, 1.03; 95% CI, 0.59-1.80; P = .91). The protective effect of the following statins on OAG risk did not differ compared with atorvastatin, an inexpensive generic statin: lovastatin (HR, 1.09; 95% CI, 0.71-1.68; P = .69), cerivastatin (HR, 0.61; 95% CI, 0.09-4.41; P = .63), rosuvastatin (HR, 0.83; 95% CI, 0.48-1.44; P = .51), fluvastatin (HR, 0.89; 95% CI, 0.39-2.02; P = .78), pravastatin (HR, 1.29; 95% CI, 0.93-1.79; P = .13), and simvastatin (HR, 1.03; 95% CI, 0.83-1.29; P = .78). CONCLUSIONS AND RELEVANCE: Even after accounting for baseline low-density lipoprotein level, statin exposure continued to be associated with a reduction in OAG risk. Our study helps inform researchers of a reasonable daily dosage and type of statin to use when designing randomized clinical trials to assess the association between statin use and glaucoma.
引用
- Talwar N, Musch DC, Stein JD, et al. Association of Daily Dosage and Type of Statin Agent With Risk of Open-Angle Glaucoma. JAMA Ophthalmol. 2017. PMID: 28114645. doi:10.1001/jamaophthalmol.2016.5406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。